Floatz logo

Benralizumab

Bullous Pemphigoid

AstraZenecamonoclonal_antibodyPhase 3Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bullous Pemphigoid cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Benralizumab is also rated in:

bronchiectasisDormant
C
Indicative ·
37 / 100
View asset →
neoplasmDormant
C
Indicative ·
35 / 100
View asset →
carcinomaDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →